Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Trebananib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 25 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2015 to 1 Jul 2015.
- 22 Apr 2014 Planned end date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History